Abstract:The fifth edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO‐HAEM5) is the product of an evidence‐based evolution of the revised fourth edition with wide multidisciplinary consultation. Nonetheless, while every classification incorporates scientific advances and aims to improve upon the prior version, medical knowledge remains incomplete and individual neoplasms may not be easily subclassified in a given scheme. Thus, optimal classification requires ongoing study, and there are certain aspects of some entities and subtypes that require further refinements. In this review, we highlight a selection of these challenging areas to prompt more research investigations. These include (1) a 'placeholder term' of splenic B‐cell lymphoma/leukaemia with prominent nucleoli (SBLPN) to accommodate many of the splenic lymphomas previously classified as hairy cell leukaemia variant and B‐prolymphocytic leukaemia, a clear new start to define their pathobiology; (2) how best to classify BCL2 rearrangement negative follicular lymphoma including those with BCL6 rearrangement, integrating the emerging new knowledge on various germinal centre B‐cell subsets; (3) what is the spectrum of non‐IG gene partners of MYC translocation in diffuse large B‐cell lymphoma/high‐grade B‐cell lymphoma and how they impact MYC expression and clinical outcome; how best to investigate this in a routine clinical setting; and (4) how best to define high‐grade B‐cell lymphoma not otherwise specified and high‐grade B‐cell lymphoma with 11q aberrations to distinguish them from their mimics and characterise their molecular pathogenetic mechanism. Addressing these questions would provide more robust evidence to better define these entities/subtypes, improve their diagnosis and/or prognostic stratification, leading to better patient care. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma

ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma

[Lymphomas: A therapeutic update]

New developments in the treatment of follicular lymphoma/ marginal zone lymphoma (according to the Congress of the American Society of Hematology – 2020)

Non-Hodgkin's lymphomas, version 1.2013

Targeting indolent non-Hodgkin lymphoma

Classification of B-Cell Lymphomas and Immunodeficiency-Related Lymphoproliferations: What’s New?

New targeted therapies for malignant lymphoma based on molecular heterogeneity

New advances in lymphoma pathology

Lymphoma classification update: B-cell non-Hodgkin lymphomas

Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma

The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management

Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas

Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review

Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management

Update: The molecular spectrum of virus-associated high-grade B-cell non-Hodgkin lymphomas

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma

The fifth edition of the WHO classification of mature B‐cell neoplasms: open questions for research

Hodgkin lymphoma: 2022 update on diagnosis, risk‐stratification, and management